Krystal Biotech (KRYS) Surges 125% Following Positive Topline Results from GEM-3 Pivotal Trial of VYJUVEK in Patients with Dystrophic Epidermolysis Bullosa

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 5/20/2022

1. CSCO
2. TGT
3. UAA
4. TSLA
5. SPY
6. BBWI
7. CRM
8. SQ
9. AMAT
10. KSS

Go back to Krystal Biotech (KRYS) Surges 125% Following Positive Topline Results from GEM-3 Pivotal Trial of VYJUVEK in Patients with Dystrophic Epidermolysis Bullosa
(NASDAQ: KRYS) Delayed: 56.93 +1.96 (3.57%)
Previous Close $54.97    52 Week High $ 
Open $54.90    52 Week Low $ 
Day High $57.29    P/E N/A 
Day Low $54.46    EPS $ 
Volume 122,652